The role of ECMO in the treatment of patients with severe COVID-19 (Acute Respiratory Distress Syndrome (ARDS) and/or acute refractory heart failure) is not yet known. The present study will aim to report the results of the ECMO management of the most severe forms of COVID-19 through the first French ECMO registry.
The main objective of this study is to evaluate the hospital survival of COVID-19 patients supported by venovenous or venoarterial ECMO in a multicenter registry. The secondary objectives are to describe the characteristics of COVID-19 patients who have received ECMO support, to identify the risk factors associated with hospital mortality, to analyze the outcomes after ECMO weaning including survival at day 28 and day 90, and to analyze the utility of a circulatory support mobile unit in a severe pandemic Inclusions are both prospective and retrospective in order to collect data over the whole pandemic
Study Type
OBSERVATIONAL
Enrollment
761
Hospital mortality
Hospital mortality
Time frame: up to 90 days
Mortality Day 28
Mortality Day 28
Time frame: Day 28
Mortality Day 90
Mortality Day 90
Time frame: Day 90
Ventilator-free days
Ventilator-free days
Time frame: Day 28
Intensive care unit-free days
ICU-free days
Time frame: Day 28
Hospital-free days
Hospital-free days
Time frame: Day 28
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.
Angers University Hospital
Angers, France
Besançon Hospital
Besançon, France
Brest university Hospital
Brest, France
Caen University Hospital
Caen, France
Clermont ferrand University hospital
Clermont-Ferrand, France
APHP Henri Mondor Paris University Hospital
Créteil, France
Dijon University Hospital
Dijon, France
Vendée Hospital
La Roche-sur-Yon, France
Grenoble University Hospital
La Tronche, France
APHP Kremli Bicetre Paris University Hospital
Le Kremlin-Bicêtre, France
...and 34 more locations